(secondQuint)Phase I/II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer.

 A multicenter Open-label, single-arm, phase I/II clinical trial is conducted on patients with histological stage IV gastric cancer given irinotecan plus S-1.

 The usefulness of this regimens as 1st line therapy for gastric cancer was evaluated by the disease-free survival rate (DFR), overall survival rate (OS), incidence and severity of adverse event.

.

 Phase I/II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer@highlight

To assess the usefulness of irinotecan plus S-1 therapy based on the antitumor effect and survival period.

 by performing a phase I/II study of this combination in patients with inoperable or with postoperative gastric cancer